Trial Profile
Atomoxetine for attention deficits in adults with mild HD [Huntington's disease]: a randomized, placebo-controlled crossover study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2018
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Huntington's disease
- Focus Therapeutic Use
- 16 Feb 2010 Actual end date (1 Feb 2008) added as reported by ClinicalTrials.gov record.
- 16 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
- 31 Oct 2009 Results were published in the Journal of Clinical Psychopharmacology.